# A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Source: https://onco.cc/trials/nct06496490/  
OnCo record `nct06496490` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TQB2102 in non-small-cell lung cancer and small-cell lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality is a phase 2 interventional study registered as NCT06496490 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 270 participants planned, started 2024-08-06 and due to reach its primary completion in 2026-06. Interventions recorded: TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06496490
- Phase: 2
- Setting: A Phase 2 Clinical Trial of TQB2102 for Injection in Locally Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Gene Abnormality to Evaluate the Efficacy and Safety
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT06496490: https://clinicaltrials.gov/study/NCT06496490

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [TQB2102](https://onco.cc/drugs/tqb2102/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06496490.json